MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Perrigo Co PLC

Closed

SectorHealthcare

26.87 -3.69

Overview

Share price change

24h

Current

Min

26.81

Max

27.9

Key metrics

By Trading Economics

Income

-24M

-45M

Sales

51M

1.1B

P/E

Sector Avg

2,570

63.778

EPS

0.93

Dividend yield

4.14

Profit margin

-3.909

Employees

8,379

EBITDA

35M

114M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+19.42% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.14%

2.39%

Next Earnings

6 maj 2025

Next Dividend date

17 cze 2025

Next Ex Dividend date

29 maj 2025

Market Stats

By TradingEconomics

Market Cap

459M

3.8B

Previous open

30.56

Previous close

26.87

News Sentiment

By Acuity

35%

65%

122 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Perrigo Co PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 lut 2025, 17:42 UTC

Major Market Movers

Perrigo Shares Jump on FDA's Move to Reclassify Wisconsin Infant-Formula Plant

27 lut 2025, 23:52 UTC

Earnings

Perrigo Gets Facility Reclassification From FDA as 4Q Profit, Revenue Fall

Peer Comparison

Price change

Perrigo Co PLC Forecast

Price Target

By TipRanks

19.42% upside

12 Months Forecast

Average 33.33 USD  19.42%

High 42 USD

Low 27 USD

Based on 4 Wall Street analysts offering 12 month price targets forPerrigo Co PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

1

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

27.74 / 28.055Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

122 / 386 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Perrigo Co PLC

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.